Apollo Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50-60 Station Rd, Cambridge, Cambridgesh...Phone Number
+44 1438906842Website
www.apollotx.comRevenue
$16.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Apollo Therapeutics
Apollo Therapeutics is a unique collaboration between three global pharmaceutical companies (AstraZeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC, Inc.) and the technology transfer offices (TTOs) responsible for commercialising the research from Imperial College London, IP Group, UCL (University College London) and the University of Cambridge. Apollo offers drug discovery expertise and translational research funding for early-stage therapeutics projects arising from the three universities.Explore more
Popular SearchesApollo Therapeutics LLPApollo TherapeuticsApollo Therapeutics LtdApollo Therapeutics LLCApollotherapeuticsSIC Code 87,873NAICS Code 54,541Show moreApollo Therapeutics Org Chart
MM
Director, Program & Portfolio Strategy
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apollo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Apollo Therapeutics
Check if Apollo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Apollo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Apollo Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Apollo Therapeutics recently announced quarterly report
Product Launch: Get notified when Apollo Therapeutics launches new products
Click to see if Apollo Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Apollo Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Apollo Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Apollo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Apollo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Apollo Therapeutics.
Apollo Therapeutics financials insights
Gather financial insights about Apollo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$145M
2023
Series C
$226.5M
2024
Series C
$33.5M
Apollo Therapeutics Tech Stack
A closer look at the technologies used by Apollo Therapeutics
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Apollo Therapeutics News & Media
Apollo Therapeutics and the University of Oxford Enter Into Drug Discovery and Development Collaboration
OXFORD, England & BOSTON--(BUSINESS WIRE)--The University of Oxford (“Oxford”), one of the world’s leading research institutions and Apollo Therapeutics (“Apollo”), a portfolio biopharmaceutical company, announce the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford. Under the agreement, Apollo will identify and assess novel, validated therapeutic targets from Oxford’s researchers for their potential to become iApollo Therapeutics Raises $33.5M In Second Close of Series C
Apollo Therapeutics, a Cambridge, UK and Boston, MA- and and Chicago, IL-based portfolio biopharmaceutical company focused on translating fundamental medical... Read More The post Apollo Therapeutics Raises $33.5M In Second Close of Series C appeared first on citybiz.Apollo Therapeutics Holds USD33.5M Second Close of Series C; Brings Round Total to $260M
Apollo Therapeutics, a Cambridge, UK and Boston, MA- and and Chicago, IL-based portfolio biopharmaceutical company focused on translating fundamental medical research into medicines, raised USD 33.5M in a second close of its Series C financing. The round, which brought the total amount to $260M, was led by Patient Square Capital and included participation by multiple […] The post Apollo Therapeutics Holds USD33.5M Second Close of Series C; Brings Round Total to $260M appeared first onApollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Apollo Therapeutics announces that it has completed a second close of its Series C, bringing the total raised in this round to $260m.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Apollo Therapeutics
Sign Up For FreeTo access detailed company insights
Apollo Therapeutics is a unique collaboration between three global pharmaceutical companies (AstraZeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC, Inc.) and the technology transfer offices (TTOs) responsible for commercialising the research from Imperial College London, IP Group, UCL (University College London) and the... Read More
